A Phase 4 interventional study of Pitavastatin (NK-104) and Lopinavir/ritonavir in Healthy Volunteers, sponsored by Kowa Research Institute, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-22.
Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 4, single center, open label, fixed-sequence, 2-way drug-drug interaction study.
This is a Phase 4, single center, open label, fixed-sequence, 2-way drug-drug interaction study.
Each subject will qualify for entry into the study not more than 30 days prior to admission into the clinical unit. Subjects will check into the clinical unit on Day -1 for baseline assessments. There will be one treatment period, with each subject receiving a once daily dose of pitavastatin 4 mg on Days 1 through 5 and Days 20 through 24 and a twice daily dose of lopinavir/ritonavir 400 mg/100 mg (two 200 mg/50 mg tablets per dose) on Days 9 through 24. Pitavastatin will be administered under fasting conditions in the morning and lopinavir/ritonavir will be administered under fasting conditions in the morning and evening.
Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy adult subjects
Drug: Pitavastatin (NK-104) · Drug: Lopinavir/ritonavir
pitavastatin (NK-104) 4 mg once daily (QD)
Also known as: Livalo
lopinavir/ritonavir 800 mg/200 mg
Also known as: Kaletra
Area Under the Curve From Time 0 to Tau (AUC 0-τ)
Area under the curve from start to elimination.
Time frame: 0, 1, 2, 3, 4, 5, 6, 8, and 12 hours after dosing on days 19 and 24
| Milestone | All Subjects |
|---|---|
| Started | 24 |
| Completed | 23 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Area under the curve from start to elimination.
| ng•h/mL | All Subjects |
|---|---|
| Area Under the Curve From Time 0 to Tau (AUC 0-τ) | 113.92 ± 53.80 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Subjects | — | 0/24 (0%) | 18/24 (75%) |
| Event | All Subjects |
|---|---|
| DiarrheaGastrointestinal disorders | 13/24 |
| Abdominal painGastrointestinal disorders | 10/24 |
| NauseaGastrointestinal disorders | 8/24 |
| HeadacheNervous system disorders | 6/24 |
| Anal hemorrhageGastrointestinal disorders | 4/24 |
| FlatulenceGastrointestinal disorders | 4/24 |
| DyspepsiaGastrointestinal disorders | 3/24 |
| DysgeusiaNervous system disorders | 3/24 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/24 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 3/24 |
| Age, Categorical(Participants) | All Subjects |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 24 |
| >=65 years | 0 |
| Age, Continuous(years) | All Subjects |
|---|---|
| Mean | 33.8 ± 8.24 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 12 |
| Male | 12 |
| Region of Enrollment(participants) | All Subjects |
|---|---|
| United States | 24 |
The record gives a start of Jan 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin
Kowa Research Institute, Inc. →